Perceptive Advisors Llc - May 31, 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Signature
/s/ Joseph Edelman - for Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its investment manager, By: Joseph Edelman, its managing member
Stock symbol
LYRA
Transactions as of
May 31, 2023
Transactions value $
$8,999,999
Form type
4
Date filed
6/2/2023, 04:11 PM
Previous filing
Jun 1, 2023
Next filing
Jun 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYRA Common Stock Purchase $9M +3.61M +45.95% $2.49 11.5M May 31, 2023 See Footnotes F1, F3, F4
holding LYRA Common Stock 1.29M May 31, 2023 See Footnotes F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Common Stock Purchase Warrant Purchase +1.81M 1.81M May 31, 2023 Common Stock 1.81M $2.67 See Footnote F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The securities reported in this row are held by Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund").
F2 The securities reported in this row are held by Perceptive LS (A), LLC ("Perceptive LS").
F3 Perceptive Advisors, LLC (the "Advisor") serves as the investment advisor to the Master Fund. Perceptive LS GP, LLC ("GP") is the manager of Perceptive LS. Joseph Edelman is the managing member of the Advisor and the sole member of GP. Each of Mr. Edelman, GP and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that Mr. Edelman, GP or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.
F4 These securities were acquired in units, with each unit consisting of one share of Common Stock and one Common Stock Purchase Warrant to purchase one share of Common Stock (the "Warrants"), at a combined purchase price of $2.4925 per unit. Each of the Warrants may not be exercised if the Reporting Persons and their affiliates would beneficially own more than 9.9% of the Issuer's outstanding shares of Common Stock following such exercise.